{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,19]],"date-time":"2026-11-19T04:05:45Z","timestamp":1795061145974,"version":"4.10.2"},"reference-count":66,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2009,11,1]],"date-time":"2009-11-01T00:00:00Z","timestamp":1257033600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2009,11]]},"DOI":"10.1016\/j.euroneuro.2009.07.008","type":"journal-article","created":{"date-parts":[[2009,8,29]],"date-time":"2009-08-29T05:49:11Z","timestamp":1251524951000},"page":"822-834","source":"Crossref","is-referenced-by-count":45,"title":["Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study"],"prefix":"10.1016","volume":"19","author":[{"given":"Grazia","family":"Dell'Agnello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dino","family":"Maschietto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Bravaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo","family":"Calamoneri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Masi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Curatolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dante","family":"Besana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Mancini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynne","family":"Poole","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Escobar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Zuddas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2009.07.008_bib1","first-page":"521","article-title":"Fenfluramine and methylphenidate in children with mental retardation and borderline IQ: clinical effects","volume":"101","author":"Aman","year":"1997","journal-title":"Am. J. Ment. Retard."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1089\/cap.2007.0066","article-title":"Efficacy and safety of atomoxetine in adolescents with attention-deficit\/hyperactivity disorder and major depression","volume":"17","author":"Bangs","year":"2007","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib3","doi-asserted-by":"crossref","first-page":"e314","DOI":"10.1542\/peds.2006-1880","article-title":"Atomoxetine for the treatment of attention-deficit\/hyperactivity disorder and oppositional defiant disorder","volume":"121","author":"Bangs","year":"2008","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib4","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1469-7610.2004.00214.x","article-title":"Young adult follow-up of hyperactive children: antisocial activities and drug use","volume":"45","author":"Barkley","year":"2004","journal-title":"J. Child. Psychol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib5","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.chi.0000189134.97436.e2","article-title":"Young adult outcome of hyperactive children: adaptive functioning in major life activities","volume":"45","author":"Barkley","year":"2006","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib6","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1542\/peds.110.6.e75","article-title":"Efficacy of atomoxetine versus placebo in school-age girls with attention-deficit\/hyperactivity disorder","volume":"110","author":"Biederman","year":"2002","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00213-006-0565-2","article-title":"Effect of comorbid symptoms of oppositional defiant disorder on responses to atomoxetine in children with ADHD: a meta-analysis of controlled clinical trial data","volume":"190","author":"Biederman","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1097\/00004583-199704000-00018","article-title":"The Screen for Child Anxiety Related Emotional Disorders (SCARED): scale construction and psychometric characteristics","volume":"36","author":"Birmaher","year":"1997","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib9","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1097\/00004583-199910000-00011","article-title":"Psychometric properties of the Screen for Child Anxiety Related Emotional Disorders Scale (SCARED): a replication study","volume":"38","author":"Birmaher","year":"1999","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib10","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1177\/0009922806294219","article-title":"Atomoxetine in the management of children with ADHD: effects on quality of life and school functioning","volume":"45","author":"Brown","year":"2006","journal-title":"Clin. Pediatr. (Phila)"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1207\/s15374424jccp2703_10","article-title":"Effects of methylphenidate on aggressive urban children with attention-deficit hyperactivity disorder","volume":"27","author":"Bukstein","year":"1998","journal-title":"J. Clin. Child. Psychol."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib12","first-page":"587","article-title":"Il Disturbo da Deficit dell'Attenzione-Iperattivit\u00e0: analisi della frequenza in una popolazione scolastica attraverso questionari agli insegnanti","volume":"63","author":"Camerini","year":"1996","journal-title":"Psichiatria. dell'infanzia. e. dell'adolescenza"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib13","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1592\/phco.24.11.1020.36146","article-title":"Atomoxetine, a novel treatment for attention-deficit\u2013hyperactivity disorder","volume":"24","author":"Christman","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib14","series-title":"Conners' Rating Scales-Revised, Technical Manual","author":"Conners","year":"1997"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1097\/00004583-200203000-00004","article-title":"Psychopharmacology and aggression: I: a meta-analysis of stimulant effects on overt\/covert aggression-related behaviors in ADHD","volume":"41","author":"Connor","year":"2002","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib16","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1093\/ajhp\/61.22.2391","article-title":"Atomoxetine: the first nonstimulant for the management of attention-deficit\/hyperactivity disorder","volume":"61","author":"Corman","year":"2004","journal-title":"Am. J. Health. Syst. Pharm."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib17","doi-asserted-by":"crossref","first-page":"e364","DOI":"10.1542\/peds.2005-0386","article-title":"Worse quality of life in children newly diagnosed with Attention Deficit\/Hyperactivity Disorder (ADHD) compared with asthmatic and healthy children","volume":"116","author":"Escobar","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib18","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1111\/j.1469-7610.1993.tb01097.x","article-title":"The effects of conduct disorder and attention deficit in middle childhood on offending and scholastic ability at age 13","volume":"34","author":"Fergusson","year":"1993","journal-title":"J. Child. Psychol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1469-7610.1997.tb01690.x","article-title":"Attentional difficulties in middle childhood and psychosocial outcomes in young adulthood","volume":"38","author":"Fergusson","year":"1997","journal-title":"J. Child. Psychol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib20","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1097\/00004583-199309000-00026","article-title":"Symptoms of attention-deficit hyperactivity disorder in an Italian school sample: findings of a pilot study","volume":"32","author":"Gallucci","year":"1993","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1023\/A:1025775311259","article-title":"Behavioral characteristics of DSM-IV ADHD subtypes in a school-based population","volume":"25","author":"Gaub","year":"1997","journal-title":"J. Abnorm. Child. Psychol."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib22","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1097\/chi.0b013e3180ca8385","article-title":"Atomoxetine treatment for pediatric patients with attention-deficit\/hyperactivity disorder with comorbid anxiety disorder","volume":"46","author":"Geller","year":"2007","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib23","series-title":"Bethesda (MD), US Dept. of Health, Education and Welfare","article-title":"ECDEU assessment manual for psychopharmacology, revised","author":"Guy","year":"1976"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00787-006-0506-y","article-title":"Comorbid oppositional defiant disorder and the risk of relapse during 9\u00a0months of atomoxetine treatment for attention-deficit\/hyperactivity disorder","volume":"15","author":"Hazell","year":"2006","journal-title":"Eur. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib25","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1037\/0022-006X.57.5.636","article-title":"Aggressive, prosocial and non-social behavior in hyperactive boys: dose effects of methylphenidate in naturalistic settings","volume":"57","author":"Hinshaw","year":"1989","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib26","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1037\/0022-006X.60.2.274","article-title":"Covert antisocial behavior in boys with attention-deficit hyperactivity disorder: external validation and effects of methylphenidate","volume":"60","author":"Hinshaw","year":"1992","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib27","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/108705470400800202","article-title":"Efficacy and safety of atomoxetine in childhood attention-deficit\/hyperactivity disorder with comorbid oppositional defiant disorder","volume":"8","author":"Kaplan","year":"2004","journal-title":"J. Atten. Disord"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1542\/peds.114.1.e1","article-title":"Once-daily atomoxetine treatment for children with attention-deficit\/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial","volume":"114","author":"Kelsey","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib29","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/ajmg.b.30072","article-title":"Phenotype studies of the DRD4 gene polymorphisms in ADHD: association with oppositional defiant disorder and positive family history","volume":"131","author":"Kirley","year":"2004","journal-title":"Am. J. Med. Genet. B. Neuropsychiatr. Genet"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib30","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1001\/archpsyc.1997.01830240023003","article-title":"Clinical efficacy of methylphenidate in conduct disorder with and without attention-deficit hyperactivity disorder","volume":"54","author":"Klein","year":"1997","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib31","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1097\/00004583-199905000-00020","article-title":"Methylphenidate and behavior modification in children with ADHD and comorbid ODD or CD: main and incremental effects across settings","volume":"38","author":"Kolko","year":"1999","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib32","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1097\/00004583-199712000-00020","article-title":"Impact of comorbid oppositional or conduct problems on attention-deficit hyperactivity disorder","volume":"36","author":"Kuhne","year":"1997","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib33","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1097\/00004583-200112000-00009","article-title":"Oppositional defiant disorder with onset in preschool years: longitudinal stability and pathways to other disorders","volume":"40","author":"Lavigne","year":"2001","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib34","doi-asserted-by":"crossref","first-page":"E83","DOI":"10.1542\/peds.108.5.e83","article-title":"Atomoxetine in the treatment of children and adolescents with attention-deficit\/hyperactivity disorder: a randomized, placebo-controlled, dose\u2013response study","volume":"108","author":"Michelson","year":"2001","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib35","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1176\/appi.ajp.159.11.1896","article-title":"Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study","volume":"159","author":"Michelson","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib36","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/archpsyc.56.12.1088","article-title":"Moderators and mediators of treatment response for children with attention-deficit\/hyperactivity disorder","volume":"56","author":"MTA Cooperative Group","year":"1999","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib37","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.eurpsy.2005.04.011","article-title":"Teacher reports of ADHD symptoms in Italian children at the end of first grade","volume":"21","author":"Mugnaini","year":"2006","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib38","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0191-8869(98)00130-5","article-title":"The Revised Screen for Child Anxiety Related Emotional Disorders (SCARED-R): factor structure in normal children","volume":"26","author":"Muris","year":"1999","journal-title":"Person. Indiv. Diff."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib39","series-title":"Technology Appraisal, Guidance No. 13","article-title":"Guidance on the use of methylphenidate (ritalin, equasym) for attention deficit\/hyperactivity disorder (ADHD) in childhood","author":"National Institute for Clinical Excellence","year":"2000"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib40","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1097\/00004583-200503000-00008","article-title":"Atomoxetine treatment in children and adolescents with attention-deficit\/hyperactivity disorder and comorbid oppositional defiant disorder","volume":"44","author":"Newcorn","year":"2005","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib41","doi-asserted-by":"crossref","first-page":"1701","DOI":"10.1542\/peds.2005-2999","article-title":"Low-dose atomoxetine for maintenance treatment of attention-deficit\/hyperactivity disorder","volume":"118","author":"Newcorn","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib42","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/s10802-005-0935-y","article-title":"Which executive functioning deficits are associated with AD\/HD, ODD\/CD and comorbid AD\/HD+ODD\/CD?","volume":"33","author":"Oosterlaan","year":"2005","journal-title":"J. Abnorm. Child. Psychol."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib43","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1001\/archpsyc.1985.01790330028003","article-title":"Methylphenidate and children with attention-deficit disorder: dose effects on classroom academic and social behavior","volume":"42","author":"Pelham","year":"1985","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib44","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1097\/00004703-200408000-00006","article-title":"Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine","volume":"25","author":"Perwien","year":"2004","journal-title":"J. Dev. Behav. Pediatr."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib45","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1089\/cap.2006.16.713","article-title":"Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?","volume":"16","author":"Perwien","year":"2006","journal-title":"J. Child. Adolesc. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib46","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1176\/appi.ajp.164.6.942","article-title":"The worldwide prevalence of ADHD: a systematic review and metaregression analysis","volume":"164","author":"Polanczyk","year":"2007","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib47","series-title":"Children's Depression Rating Scale, Revised","author":"Poznanski","year":"1999"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib48","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1185\/030079906X167309","article-title":"A multi-centre, randomised, open-label study of atomoxetine compared with standard current therapy in UK children and adolescents with attention-deficit\/hyperactivity disorder (ADHD)","volume":"23","author":"Prasad","year":"2007","journal-title":"Curr. Med. Res. Opin."},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2009.07.008_bib49","first-page":"36","article-title":"ADORE \u2014 Attention-Deficit Hyperactivity Disorder Observational Research in Europe","volume":"13","author":"Ralston","year":"2004","journal-title":"Eur. Child. Adolesc. Psychiatry."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib50","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1097\/00005650-199808000-00011","article-title":"A taxonomy of adolescent health need: reliability and validity of the adolescent health and illness profiles","volume":"36","author":"Riley","year":"1998","journal-title":"Med. Care"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib51","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/01.mlr.0000114909.33878.ca","article-title":"The parent report form of the CHIP-Child Edition: reliability and validity","volume":"42","author":"Riley","year":"2004","journal-title":"Med. Care"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib52","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1023\/B:CHUD.0000014998.93858.1d","article-title":"The family psychosocial characteristics of children with attention-deficit hyperactivity disorder with or without oppositional or conduct problems in Japan","volume":"34","author":"Satake","year":"2004","journal-title":"Child. Psychiatry Hum. Dev."},{"issue":"Suppl. 1","key":"10.1016\/j.euroneuro.2009.07.008_bib53","first-page":"41","article-title":"Linee guida per il disturbo da deficit attentivo con iperattivit\u00e0 (ADHD) in et\u00e0 evolutiva. I: Diagnosi e terapia farmacologica","volume":"24","author":"Societ\u00e0 Italiana di NeuroPsichiatria dell'Infanzia e dell'Adolescenza (SINPIA)","year":"2004","journal-title":"Giornale di Neuropsichiatria dell'et\u00e0 evolutiva"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib54","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1176\/ajp.155.5.693","article-title":"Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder","volume":"155","author":"Spencer","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1542\/peds.2004-0624","article-title":"Effects of atomoxetine on growth after 2-year treatment among pediatric patients with attention-deficit\/hyperactivity disorder","volume":"116","author":"Spencer","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib56","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.clinthera.2006.03.006","article-title":"Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of oppositional defiant disorder with or without comorbid attention-deficit\/hyperactivity disorder in school-aged children and adolescents: a 4-week, multicenter, randomized, double-blind, parallel-group, placebo-controlled, forced-dose-escalation study","volume":"28","author":"Spencer","year":"2006","journal-title":"Clin. Ther."},{"issue":"suppl 1","key":"10.1016\/j.euroneuro.2009.07.008_bib57","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00787-006-1004-y","article-title":"Co-existing psychiatric problems in ADHD in the ADORE cohort","volume":"15","author":"Steinhausen","year":"2006","journal-title":"Eur. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib58","unstructured":"Strattera SPC (last updated on the eMC: 20\/11\/2008) (http:\/\/emc.medicines.org.uk\/emc\/assets\/c\/html\/displaydoc.asp?documentid=14482)."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib59","series-title":"School-Based Assessment and Interventions for ADD","first-page":"184","author":"Swanson","year":"1992"},{"issue":"Suppl 1","key":"10.1016\/j.euroneuro.2009.07.008_bib60","first-page":"I7","article-title":"European clinical guidelines for hyperkinetic disorder \u2014 first upgrade","volume":"13","author":"Taylor","year":"2004","journal-title":"Eur. Child. Adolesc. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib61","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1111\/j.1469-7610.2006.01724.x","article-title":"Which better predicts conduct problems? The relationship of trajectories of conduct problems with ODD and ADHD symptoms from childhood into adolescence","volume":"48","author":"van Lier","year":"2007","journal-title":"J. Child. Psychol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib62","series-title":"Trento, Edizioni Erickson","article-title":"Il bambino con deficit di attenzione\/iperattivit\u00e0","author":"Vio","year":"1999"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib63","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1097\/01.chi.0000163280.47221.c9","article-title":"A randomized, placebo-controlled study of once-daily atomoxetine in the school setting in children with ADHD","volume":"44","author":"Weiss","year":"2005","journal-title":"J. Am. Acad. Child. Adolesc. Psychiatry"},{"issue":"Suppl 12","key":"10.1016\/j.euroneuro.2009.07.008_bib64","first-page":"50","article-title":"Safety profile of atomoxetine in the treatment of children and adolescents with ADHD","volume":"63","author":"Wernicke","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2009.07.008_bib65","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/00002018-200326100-00006","article-title":"Cardiovascular effects of atomoxetine in children, adolescents, and adults","volume":"26","author":"Wernicke","year":"2003","journal-title":"Drug. Saf."},{"key":"10.1016\/j.euroneuro.2009.07.008_bib66","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eurpsy.2005.08.001","article-title":"Factor structure and cultural factors of disruptive behaviour disorders symptoms in Italian children","volume":"21","author":"Zuddas","year":"2006","journal-title":"Eur. Psychiatry"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X0900193X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X0900193X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T04:25:49Z","timestamp":1558499149000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X0900193X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11]]},"references-count":66,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2009,11]]}},"alternative-id":["S0924977X0900193X"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2009.07.008","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11]]}}}